Severity of Respiratory Syncytial Virus and Other Respiratory Viruses Versus Seasonal Influenza Among Hospitalized Patients With Cancer - Scorecard - MDSpire
Advertisement
Severity of Respiratory Syncytial Virus and Other Respiratory Viruses Versus Seasonal Influenza Among Hospitalized Patients With Cancer
Clinical Scorecard: Comparative Analysis of Respiratory Syncytial Virus and Other Respiratory Infections Against Seasonal Influenza in Hospitalized Cancer Patients
At a Glance
Category
Detail
Condition
Respiratory viral infections (RVIs) in hospitalized hematology/oncology patients
Key Mechanisms
Immunocompromise in cancer patients increases susceptibility and severity of RVIs; year-round transmission in tropical climates; multiplex PCR testing enables detection of multiple RVIs
Target Population
Adult hospitalized patients with cancer and respiratory viral infections
Care Setting
Tertiary hospital inpatient setting specializing in cancer care
Key Highlights
RSV and other non-vaccine-preventable RVIs (HMPV, adenovirus) cause more severe outcomes than seasonal influenza in hospitalized cancer patients.
Severe infection occurred in 29.4% of patients, with 14.8% mortality within 1 month of admission.
Older age, comorbidities, coinfections, and nosocomial transmission are associated with increased severity of RVIs.
Guideline-Based Recommendations
Diagnosis
Use multiplex polymerase chain reaction (PCR) testing for simultaneous detection of multiple respiratory viral infections in cancer patients.
Management
Prioritize infection prevention measures to reduce nosocomial transmission in immunocompromised cancer patients.
Recognize RSV and other RVIs as causes of severe disease requiring intensive care and close monitoring.
Monitoring & Follow-up
Monitor for oxygen requirement, ICU/high-dependency admission, and mortality within 1 month as markers of severe infection.
Risks
Consider older age, presence of comorbid conditions, coinfections, and hospital-acquired infections as risk factors for severe RVI outcomes.
Patient & Prescribing Data
Hospitalized adult cancer patients with respiratory viral infections
Current preventive options are limited to influenza and RSV vaccines; new vaccines and therapeutics are needed for other RVIs such as HMPV and adenovirus.
Clinical Best Practices
Implement multiplex PCR testing for comprehensive RVI diagnosis in cancer inpatients.
Enforce strict infection control protocols to prevent nosocomial RVI outbreaks.
Identify high-risk patients (older, comorbidities, coinfections) for intensified monitoring and supportive care.
Advocate for development and use of new vaccines and therapeutics targeting non-influenza RVIs.
by Liang En Wee, Leicester Shawn Alcantara, May Kyawt Aung, Shalvi Arora, Jean Xiang Ying Sim, Dong Dong Ren, Zachary Allen Vincent, Veeramani Srivathsan, Tertius Tansloan Tuy, Shin Yeu Ong, Wei Chong Tan, Iain Beehuat Tan, Limin Wijaya, Indumathi Venkatachalam, Kelvin Bryan Tan, Benjamin W Teh, Ban Hock Tan
